AC Immune SA Aktie News

Alle primären Endpunkte der Studie wurden erreicht, ACI‑7104 erwies sich als allgemein sicher und gut verträglich Starke Immunogenität nachgewiesen, mit 100 % Responserate nach drei Immunisierungen Klare Antikörperpenetration in die Liquor cerebrospinalis (CSF) und Signale für Target‑Engagement Gespräche mit der FDA über den weiteren Entwicklungsweg geplant für Anfang 2027 AC Immune veranstalte...

AC Immune meldete positive interimistische Phase-1-Ergebnisse aus einer First-in-Human-Studie zur Bewertung von ACI-19764, einem NLRP3-Inhibitor, der auf Entzündungen abzielt.

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease supported by a $4 million grant from The Vijay and Marie Go...

AC Immune wird die Pipeline für neurodegenerative Erkrankungen mit drei Präsentationen auf der Alzheimer's Association International Conference® 2026 vorstellen Lausanne, Schweiz, 7. Juli 2026 -- AC Immune SA (NASDAQ: ACIU), ein biopharmazeutisches Unternehmen im klinischen Stadium, das präzisionsbasierte Therapeutika für neurodegenerative Erkrankungen vorantreibt, kündigt heute drei Präsentati...

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer's disease (AD) cohorts in ABATE Anti-Abeta antibody dose-response demonstrated with antibodies detected at all dose levels in cohorts AD1-3 Ongoing AD4 cohort includes additional adjuvant ...

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years Final data from Part 1 of VacSYn trial expected in H2 2026 Lausanne, Switzerland, June 11, 2026 -- AC Immune SA...

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS) Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD) Underlines potential for precisi...

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care